{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:26:17Z","timestamp":1779114377373,"version":"3.51.4"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-grade serous carcinoma (HGSC) of the ovary remains the deadliest gynecologic cancer, with 5-year survival rates of less than 50%. Remission is usually achieved by surgical debulking and chemotherapy, but most (\u223c70%) of patients ultimately develop treatment-resistant disease. Infiltration of immune cells into the HGSC microenvironment, including natural killer (NK) cells, is associated with lengthened overall and progression-free survival, suggesting that immunosurveillance contributes to HGSC control. The mechanisms permitting or prohibiting anticancer activity are unclear, but if understood, they might shed light on opportunities for immunotherapy or precision medicine. We investigated the interactions between NK cells and adenosine, an immunosuppressive metabolite that concentrates in HGSC. Exposure of HGSC to adenosine induces upregulation of ligands associated with NK cell inhibition, including HLA-E. On NK cells, adenosine induces upregulation of the cognate inhibitory receptor for HLA-E, natural killer group 2A (NKG2A). The CD16low NK cell subset was most responsive to the HGSC cell line, OVCAR4, but also more likely to upregulate NKG2A and become inhibited after adenosine treatment. A single nucleotide polymorphism (SNP) in the gene for NKG2A (V5: rs2734440 C) encodes for higher NKG2A surface expression and a stronger inhibitory response to HLA-E-expressing targets. Here, we demonstrate that NK cell suppression in the context of adenosine is most profound in NK cells homozygous for the V5 variant. Our results reveal a novel link between metabolism and immunologic inhibition and highlight the KLRC1-V5 variant as a putative biomarker for response to anti-NKG2A therapy and\/or susceptibility to adenosine-driven immunosuppression.<\/jats:p>","DOI":"10.1093\/jleuko\/qiag032","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:46:32Z","timestamp":1772887592000},"source":"Crossref","is-referenced-by-count":1,"title":["Adenosine drives suppression of CD16low NK cell responses against HGSC via NKG2A:hLA-E interactions"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-8498","authenticated-orcid":false,"given":"Anna P","family":"Nicolela","sequence":"first","affiliation":[{"name":"Department of Pathology, Dalhousie University, Sir Charles Tupper Medical Buildling, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]},{"name":"Beatrice Hunter Cancer Research Institute"},{"name":"Faculty of Medicine, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-2077","authenticated-orcid":false,"given":"Sarah","family":"Nersesian","sequence":"additional","affiliation":[{"name":"Beatrice Hunter Cancer Research Institute"},{"name":"Department of Microbiology & Immunology, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6518-8006","authenticated-orcid":false,"given":"Stacey N","family":"Lee","sequence":"additional","affiliation":[{"name":"Beatrice Hunter Cancer Research Institute"},{"name":"Department of Microbiology & Immunology, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breanna K V","family":"Hargreaves","sequence":"additional","affiliation":[{"name":"Beatrice Hunter Cancer Research Institute"},{"name":"Faculty of Medicine, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]},{"name":"Department of Microbiology & Immunology, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-2180","authenticated-orcid":false,"given":"Jeanette E","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dalhousie University, Sir Charles Tupper Medical Buildling, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]},{"name":"Beatrice Hunter Cancer Research Institute"},{"name":"Department of Microbiology & Immunology, Dalhousie University, Sir Charles Tupper Medical Building, 5850 College St. Halifax, NS, B3H 4R2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026032413021567400_qiag032-B1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"2026032413021567400_qiag032-B2","volume-title":"Statpearls","author":"Arora","year":"2025"},{"key":"2026032413021567400_qiag032-B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"2026032413021567400_qiag032-B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"2026032413021567400_qiag032-B5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12885-018-4242-8","article-title":"Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers","volume":"18","author":"Le Page","year":"2018","journal-title":"BMC Cancer"},{"key":"2026032413021567400_qiag032-B6","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.3390\/cancers15225356","article-title":"New achievements from molecular biology and treatment options for refractory\/relapsed ovarian cancer-a systematic review","volume":"15","author":"Bachmann","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2026032413021567400_qiag032-B7","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026032413021567400_qiag032-B8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-019-0541-0","article-title":"An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)","volume":"7","author":"Clouthier","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026032413021567400_qiag032-B9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol."},{"key":"2026032413021567400_qiag032-B10","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J Clin Oncol."},{"key":"2026032413021567400_qiag032-B11","doi-asserted-by":"publisher","first-page":"10656","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes","volume":"108","author":"Gooden","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026032413021567400_qiag032-B12","doi-asserted-by":"publisher","first-page":"1307873","DOI":"10.3389\/fimmu.2023.1307873","article-title":"Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages","volume":"14","author":"Nersesian","year":"2024","journal-title":"Front Immunol."},{"key":"2026032413021567400_qiag032-B13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026032413021567400_qiag032-B14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/0284186X.2019.1711173","article-title":"Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma","volume":"59","author":"Henriksen","year":"2020","journal-title":"Acta Oncol"},{"key":"2026032413021567400_qiag032-B15","doi-asserted-by":"publisher","first-page":"e1127496","DOI":"10.1080\/2162402X.2015.1127496","article-title":"CD73-adenosine reduces immune responses and survival in ovarian cancer patients","volume":"5","author":"Gaudreau","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026032413021567400_qiag032-B16","doi-asserted-by":"publisher","first-page":"100930","DOI":"10.1016\/j.tranon.2020.100930","article-title":"NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis","volume":"14","author":"Nersesian","year":"2020","journal-title":"Transl Oncol."},{"key":"2026032413021567400_qiag032-B17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11864-021-00929-x","article-title":"Natural killer cells: the missing link in effective treatment for high-grade serous ovarian carcinoma","volume":"23","author":"Pugh-Toole","year":"2022","journal-title":"Curr Treat Options Oncol."},{"key":"2026032413021567400_qiag032-B18","doi-asserted-by":"publisher","first-page":"1269614","DOI":"10.3389\/fimmu.2023.1269614","article-title":"Killer instincts: natural killer cells as multifactorial cancer immunotherapy","volume":"14","author":"Nersesian","year":"2023","journal-title":"Front Immunol."},{"key":"2026032413021567400_qiag032-B19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural killer cell education and the response to infection and cancer therapy: stay tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol"},{"key":"2026032413021567400_qiag032-B20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.immuni.2016.07.005","article-title":"Cell-extrinsic MHC class I molecule engagement augments human NK cell education programmed by cell-intrinsic MHC class I","volume":"45","author":"Boudreau","year":"2016","journal-title":"Immunity"},{"key":"2026032413021567400_qiag032-B21","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1002\/1521-4141(2001010)31:10%253C3121::aid-immu3121%253E3.0.co;2-4","article-title":"CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells","volume":"31","author":"Jacobs","year":"2001","journal-title":"Eur J Immunol."},{"key":"2026032413021567400_qiag032-B22","doi-asserted-by":"publisher","first-page":"e11966","DOI":"10.1371\/journal.pone.0011966","article-title":"NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs","volume":"5","author":"B\u00e9ziat","year":"2010","journal-title":"PLoS One"},{"key":"2026032413021567400_qiag032-B23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41590-023-01523-z","article-title":"HLA class I signal peptide polymorphism determines the level of CD94\/NKG2\u2013HLA-E-mediated regulation of effector cell responses","volume":"24","author":"Lin","year":"2023","journal-title":"Nat Immunol."},{"key":"2026032413021567400_qiag032-B24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1084\/jem.185.4.795","article-title":"NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor","volume":"185","author":"Brooks","year":"1997","journal-title":"J Exp Med."},{"key":"2026032413021567400_qiag032-B25","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1182\/bloodadvances.2024013508","article-title":"Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function","volume":"8","author":"Le Luduec","year":"2024","journal-title":"Blood Adv"},{"key":"2026032413021567400_qiag032-B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/QAD.0b013e3283328d1f","article-title":"Chronic HIV-1 viremia reverses NKG2A\/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection","volume":"24","author":"Brunetta","year":"2010","journal-title":"AIDS"},{"key":"2026032413021567400_qiag032-B27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3389\/fimmu.2017.01176","article-title":"NKG2C + NKG2A\u2212 natural killer cells are associated with a lower viral set point and may predict disease progression in individuals with primary HIV infection","volume":"8","author":"Ma","year":"2017","journal-title":"Front Immunol."},{"key":"2026032413021567400_qiag032-B28","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1073\/pnas.0802736105","article-title":"Structural basis for NKG2A\/CD94 recognition of HLA-E","volume":"105","author":"Kaiser","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026032413021567400_qiag032-B29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/cas.12641","article-title":"Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer","volume":"106","author":"Zheng","year":"2015","journal-title":"Cancer Sci"},{"key":"2026032413021567400_qiag032-B30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13048-023-01286-z","article-title":"IFN-\u03b3 in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis","volume":"16","author":"Zheng","year":"2023","journal-title":"J Ovarian Res."},{"key":"2026032413021567400_qiag032-B31","doi-asserted-by":"publisher","first-page":"e001965","DOI":"10.1136\/jitc-2020-001965","article-title":"High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer","volume":"9","author":"Bareche","year":"2021","journal-title":"J Immunother Cancer."},{"key":"2026032413021567400_qiag032-B32","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","article-title":"Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response","volume":"26","author":"Sidders","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2026032413021567400_qiag032-B33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1096\/fj.05-4804fje","article-title":"Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils","volume":"20","author":"McColl","year":"2006","journal-title":"FASEB J"},{"key":"2026032413021567400_qiag032-B34","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3389\/fimmu.2018.02533","article-title":"Adenosinergic signaling alters natural killer cell functional responses","volume":"9","author":"Chambers","year":"2018","journal-title":"Front Immunol."},{"key":"2026032413021567400_qiag032-B35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat Immunol."},{"key":"2026032413021567400_qiag032-B36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40246-024-00651-3","article-title":"Integrated multiomics revealed adenosine signaling predict immunotherapy response and regulate tumor ecosystem of melanoma","volume":"18","author":"Xu","year":"2024","journal-title":"Hum Genomics."},{"key":"2026032413021567400_qiag032-B37","first-page":"2602","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Res"},{"key":"2026032413021567400_qiag032-B38","doi-asserted-by":"publisher","first-page":"e010126","DOI":"10.1136\/jitc-2024-010126","article-title":"Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation","volume":"13","author":"Sun","year":"2025","journal-title":"J Immunother Cancer."},{"key":"2026032413021567400_qiag032-B39","doi-asserted-by":"publisher","first-page":"100824","DOI":"10.1016\/j.neo.2022.100824","article-title":"Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy","volume":"32","author":"Guan","year":"2022","journal-title":"Neoplasia"},{"key":"2026032413021567400_qiag032-B40","doi-asserted-by":"publisher","first-page":"14711","DOI":"10.1073\/pnas.1308209110","article-title":"Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors","volume":"110","author":"Beavis","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026032413021567400_qiag032-B41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1158\/0008-5472.CAN-22-2553","article-title":"CD73-dependent adenosine signaling through Adora2b drives immunosuppression in ductal pancreatic cancer","volume":"83","author":"Faraoni","year":"2023","journal-title":"Cancer Res"},{"key":"2026032413021567400_qiag032-B42","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1186\/s12967-024-05846-9","article-title":"A patient stratification signature mirrors the immunogenic potential of high grade serous ovarian cancers","volume":"22","author":"Berry","year":"2024","journal-title":"J Transl Med."},{"key":"2026032413021567400_qiag032-B43","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.4049\/jimmunol.1502469","article-title":"KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV","volume":"196","author":"Boudreau","year":"2016","journal-title":"J Immunol"},{"key":"2026032413021567400_qiag032-B44","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/s0006-2952(03)00548-3","article-title":"Adenosine stimulation of the proliferation of colorectal carcinoma cell lines. Roles of cell density and adenosine metabolism","volume":"66","author":"Mujoomdar","year":"2003","journal-title":"Biochem Pharmacol."},{"key":"2026032413021567400_qiag032-B45","volume-title":"Navigating metabolism","author":"Chandel","year":"2015"},{"key":"2026032413021567400_qiag032-B46","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s00262-022-03219-z","article-title":"Functional expression of CD73 on human natural killer cells","volume":"71","author":"Chambers","year":"2022","journal-title":"Cancer Immunol Immunother."},{"key":"2026032413021567400_qiag032-B47","doi-asserted-by":"publisher","first-page":"e007340","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer."},{"key":"2026032413021567400_qiag032-B48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2018.07.025","article-title":"Patient inflammatory status and CD4+\/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer","volume":"151","author":"Pinto","year":"2018","journal-title":"Gynecol Oncol."},{"key":"2026032413021567400_qiag032-B49","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.3390\/cancers13225783","article-title":"High density of CD16+ tumor-infiltrating immune cells in recurrent ovarian cancer is associated with enhanced responsiveness to chemotherapy and prolonged overall survival","volume":"13","author":"Lalos","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026032413021567400_qiag032-B50","doi-asserted-by":"publisher","first-page":"e179501","DOI":"10.1172\/JCI179501","article-title":"Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer","volume":"134","author":"Nelson","year":"2024","journal-title":"J Clin Invest."},{"key":"2026032413021567400_qiag032-B51","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr Oncol"},{"key":"2026032413021567400_qiag032-B52","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","article-title":"CD73 is associated with poor prognosis in high-grade serous ovarian cancer","volume":"75","author":"Turcotte","year":"2015","journal-title":"Cancer Res"},{"key":"2026032413021567400_qiag032-B53","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cti2.1230","article-title":"NKG2D and MICA\/B shedding: a \u2018tag game\u2019 between NK cells and malignant cells","volume":"9","author":"Xing","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"2026032413021567400_qiag032-B54","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"2026032413021567400_qiag032-B55","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4049\/jimmunol.143.10.3183","article-title":"Comparative studies of human FcRIII-positive and negative natural killer cells","volume":"143","author":"Nagler","year":"1989","journal-title":"J Immunol"},{"key":"2026032413021567400_qiag032-B56","doi-asserted-by":"publisher","first-page":"965","DOI":"10.4049\/jimmunol.1500591","article-title":"CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation","volume":"195","author":"Morandi","year":"2015","journal-title":"J Immunol"},{"key":"2026032413021567400_qiag032-B57","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1172\/JCI128895","article-title":"CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment","volume":"130","author":"Neo","year":"2020","journal-title":"J Clin Invest."},{"key":"2026032413021567400_qiag032-B58","doi-asserted-by":"publisher","first-page":"1199594","DOI":"10.3389\/fimmu.2023.1199594","article-title":"NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells","volume":"14","author":"Campos-Mora","year":"2023","journal-title":"Front Immunol."},{"key":"2026032413021567400_qiag032-B59","doi-asserted-by":"publisher","first-page":"eabj3286","DOI":"10.1126\/sciadv.abj3286","article-title":"When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer","volume":"8","author":"Hasim","year":"2022","journal-title":"Sci Adv."},{"key":"2026032413021567400_qiag032-B60","doi-asserted-by":"publisher","first-page":"109632","DOI":"10.1016\/j.celrep.2021.109632","article-title":"High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment","volume":"36","author":"Gonzalez","year":"2021","journal-title":"Cell Rep"},{"key":"2026032413021567400_qiag032-B61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"van Hall","year":"2019","journal-title":"J Immunother Cancer."},{"key":"2026032413021567400_qiag032-B62","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"key":"2026032413021567400_qiag032-B63","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, Phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non\u2013small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol."},{"key":"2026032413021567400_qiag032-B64","doi-asserted-by":"publisher","first-page":"e006842","DOI":"10.1136\/jitc-2023-006842","article-title":"CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models","volume":"11","author":"Ye","year":"2023","journal-title":"J Immunother Cancer."}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jleukbio\/advance-article-pdf\/doi\/10.1093\/jleuko\/qiag032\/67282349\/qiag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/118\/3\/qiag032\/67282349\/qiag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/118\/3\/qiag032\/67282349\/qiag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:02:25Z","timestamp":1774371745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/doi\/10.1093\/jleuko\/qiag032\/8512499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jleuko\/qiag032","relation":{},"ISSN":["1938-3673"],"issn-type":[{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"qiag032"}}